Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from TScan Therapeutics ( (TCRX) ) is now available.
On May 20, 2026, TScan Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where shareholders elected Katina Dorton and R. Keith Woods as Class II directors to three-year terms ending in 2029 and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. Stockholders also approved doubling the company’s authorized voting common stock from 300 million to 600 million shares, significantly expanding its potential capacity to issue new equity for financing or strategic purposes, while an adjournment proposal was approved but ultimately unnecessary as quorum and support were already sufficient.
The most recent analyst rating on (TCRX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on TScan Therapeutics stock, see the TCRX Stock Forecast page.
Spark’s Take on TCRX Stock
According to Spark, TipRanks’ AI Analyst, TCRX is a Neutral.
The score is primarily held down by weak financial performance—large losses, sustained cash burn, and declining revenue—despite strong gross margins and manageable leverage. Technicals provide some offset with improving short-term momentum, while valuation remains constrained by negative earnings and no dividend support.
To see Spark’s full report on TCRX stock, click here.
More about TScan Therapeutics
TScan Therapeutics, Inc. is a biotechnology company focused on developing therapeutics, operating within the life sciences and biopharmaceutical industry. As a publicly traded company, it is governed by a board of directors elected by stockholders and relies on an independent registered public accounting firm to audit its financial statements and support its capital markets presence.
Average Trading Volume: 859,053
Technical Sentiment Signal: Sell
Current Market Cap: $65M
Find detailed analytics on TCRX stock on TipRanks’ Stock Analysis page.